Genentech's Tecentriq combination therapy is the first maintenance treatment for extensive-stage small cell lung cancer, a significant advance in a hard-to-treat disease.
Regulators express significant doubts over the company's lead drug candidate, avacopan, sparking a massive investor sell-off.
The new oral treatment addresses chronic spontaneous urticaria in patients unresponsive to antihistamines, driving shares up over 2.7%.
Company receives a Complete Response Letter for its Menkes disease treatment, CUTX-101, citing manufacturing issues, not safety or efficacy concerns.
Designation aims to speed development of novel tau-targeting antibody for early-stage Alzheimer's disease.
Disappointing Phase 3 data for its lead drug sonelokimab triggers massive sell-off and analyst downgrades, erasing billions in market value.
Conditional approval for screwworm treatment Dectomax-CA1 opens a new revenue stream and addresses a key industry need, boosting investor confidence.
The approval marks the first oral Bruton's tyrosine kinase (BTK) inhibitor for chronic spontaneous urticaria, offering a new option for patients unresponsive to antihistamines.